OpenAI buys Orchestra Bio to expand life sciences tools
The deal adds tools for managing drug discovery operations to OpenAI’s life sciences work, which the company says already serves Moderna and Novo Nordisk.
• OpenAI is buying Orchestra Bio and adding its team and technology to Rosalind and Rosalind Workbench.
• Orchestra makes AI agents that help biotech companies manage drug discovery operations.
• Deal terms were not disclosed; Orchestra had reportedly raised around $20 million as of 2025.
Read more
October 21, 2026 23
